Conatus Pharmaceuticals Inc. (CNAT) Upcoming Presentations, Analysts Review and Target


Conatus Pharmaceuticals, Upcoming Presentations, Analysts Review and Target

Traders News Source, a leading independent equity research, and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Conatus Pharmaceuticals Inc. (CNAT), a biotechnology company, focused on the development and commercialization of novel medicines for the treatment of liver diseases.

On September 17th, CNAT shares closed at $4.16 per share and had an average trading volume under 500K. The company shares have reached a high of $6.74 since then and recent traded volume has been in the millions of shares.

CNAT clinical trials, analysts review, and target READ MORE

Copy and paste to your browser may be required to view the report –

Conatus is in a collaboration agreement with Novartis for the development of its lead drug candidate emricasan (IDN-6556). The collaboration allows for cash payments to CNAT based on certain milestones and Novartis also contributes finances for the company’s clinical trial process.

CNAT will host an invitation-only symposium on portal hypertension for institutional investors and research analysts on Thursday, September 27, 2018, from 4:30 p.m. to 6:00 p.m. ET in New York.

Novartis collaboration details and current pipeline data READ MORE

Copy and paste to your browser may be required to view the report –

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TNS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

CONTACT: [email protected]

SOURCE: Traders News Source


Please enter your comment!
Please enter your name here